Clifford Swan Investment Counsel LLC boosted its position in shares of Albemarle Co. (NYSE:ALB – Free Report) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,258 shares of the specialty chemicals company’s stock after purchasing an additional 293 shares during the period. Clifford Swan Investment Counsel LLC owned approximately 0.09% of Albemarle worth $14,630,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Eagle Strategies LLC increased its position in shares of Albemarle by 149.3% during the third quarter. Eagle Strategies LLC now owns 14,058 shares of the specialty chemicals company’s stock worth $2,391,000 after acquiring an additional 8,420 shares during the last quarter. Deutsche Bank AG increased its holdings in Albemarle by 5.4% during the 3rd quarter. Deutsche Bank AG now owns 283,876 shares of the specialty chemicals company’s stock worth $48,270,000 after purchasing an additional 14,593 shares during the last quarter. Roffman Miller Associates Inc. PA raised its position in shares of Albemarle by 430.7% in the 4th quarter. Roffman Miller Associates Inc. PA now owns 43,119 shares of the specialty chemicals company’s stock valued at $6,230,000 after purchasing an additional 34,994 shares in the last quarter. Kestra Advisory Services LLC grew its position in shares of Albemarle by 80.3% during the third quarter. Kestra Advisory Services LLC now owns 19,757 shares of the specialty chemicals company’s stock worth $3,359,000 after buying an additional 8,799 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Albemarle by 8.9% in the third quarter. Ameriprise Financial Inc. now owns 412,821 shares of the specialty chemicals company’s stock worth $70,179,000 after buying an additional 33,662 shares during the last quarter. Hedge funds and other institutional investors own 92.87% of the company’s stock.
Albemarle Stock Performance
Shares of ALB traded up $2.80 during mid-day trading on Friday, reaching $128.10. 2,600,059 shares of the company’s stock traded hands, compared to its average volume of 2,691,240. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.86 and a current ratio of 2.84. The business’s 50-day moving average price is $123.26 and its 200-day moving average price is $126.23. The stock has a market capitalization of $15.06 billion, a P/E ratio of 46.58, a price-to-earnings-growth ratio of 2.78 and a beta of 1.65. Albemarle Co. has a 12 month low of $106.69 and a 12 month high of $247.44.
Albemarle Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 15th were given a $0.40 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.60 dividend on an annualized basis and a yield of 1.25%. Albemarle’s dividend payout ratio is presently 58.18%.
Wall Street Analysts Forecast Growth
A number of research firms have commented on ALB. Wells Fargo & Company increased their price objective on shares of Albemarle from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. Royal Bank of Canada reduced their price target on shares of Albemarle from $140.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Mizuho boosted their price objective on Albemarle from $112.00 to $128.00 and gave the company a “neutral” rating in a report on Thursday. TD Cowen downgraded Albemarle from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $220.00 to $130.00 in a report on Monday, January 29th. Finally, KeyCorp lowered their price target on Albemarle from $178.00 to $159.00 and set an “overweight” rating for the company in a report on Thursday, March 7th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Albemarle currently has a consensus rating of “Hold” and a consensus target price of $175.85.
View Our Latest Analysis on ALB
About Albemarle
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.
Featured Articles
- Five stocks we like better than Albemarle
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 4/29 – 5/3
- Most active stocks: Dollar volume vs share volume
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Investing in the High PE Growth Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Co. (NYSE:ALB – Free Report).
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.